MicroRNA-193b is a regulator of amyloid precursor protein in the blood and cerebrospinal fluid derived exosomal microRNA-193b is a biomarker of Alzheimer's disease

Authors:
- Chen-Geng Liu
- Jing Song
- Yue-Qi Zhang
- Pei-Chang Wang
View Affiliations

Affiliations: Department of Clinical Laboratory, Xuanwu Hospital, Capital Medical University, Beijing 100053, P.R. China
Published online on: August 12, 2014 https://doi.org/10.3892/mmr.2014.2484
Pages: 2395-2400

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Amyloid precursor protein (APP) has an important function in the generation of Alzheimer's disease (AD). In our previous study, miR‑193b was found to be downregulated in the hippocampi of 9‑month‑old APP/PS1 double‑transgenic mice using microRNA (miR) array. In the present study, bioinformatic analyses showed that miR‑193b was a miR that was predicted to potentially target the 3'‑untranslated region (UTR) of APP. Subsequently, the function of miR‑193b on APP was studied. The levels of miR‑193b, exosomal miR‑193b, Aβ, tau, p‑tau, HCY and APOE in samples from APP/PS1 double‑transgenic mice, mild cognitive impairment (MCI) and dementia of Alzheimer‑type (DAT) patients, were measured. The results indicated that overexpression of miR‑193b could repress the mRNA and protein expression of APP. The miR‑193b inhibitor oligonucleotide induced upregulation of APP. Binding sites of miR‑193b in the 3'‑UTR of APP were identified by luciferase assay. MCI and DAT patients had lower exosomal miR‑193b, but not total miR‑193b, in the blood as compared with the controls. DAT patients had lower exosomal miR‑193b levels in blood as compared with the MCI group. A decreased exosomal miR‑193b expression level was additionally observed in the cerebral spinal fluid (CSF) of DAT patients. Negative correlations were found between exosomal miR‑193b and Aβ42 in the CSF of DAT patients. In conclusion, these findings showed that miR‑193b may function in the development of AD and exosomal miR‑193b has potential as a novel, non-invasive, blood‑based biomarker of MCI and DAT patients.

View Figures

View References

1	Lewczuk P, Kamrowski-Kruck H, Peters O, et al: Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer’s disease: a multicenter study. Mol Psychiatry. 15:138–145. 2010.
2	Weiner MW: Dementia in 2012: Further insights into Alzheimer disease pathogenesis. Nat Rev Neurol. 2:65–66. 2013. View Article : Google Scholar : PubMed/NCBI
3	Singer O, Marr RA, Rockenstein E, et al: Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci. 8:1343–1349. 2005. View Article : Google Scholar : PubMed/NCBI
4	Tan L, Yu JT, Hu N and Tan L: Non-coding RNAs in Alzheimer’s disease. Mol Neurobiol. 47:382–393. 2013.
5	Junn E and Mouradian MM: MicroRNAs in neurodegenerative diseases and their therapeutic potential. Pharmacol Ther. 133:142–150. 2012. View Article : Google Scholar : PubMed/NCBI
6	Delay C, Mandemakers W and Hébert SS: MicroRNAs in Alzheimer’s disease. Neurobiol Dis. 46:285–290. 2012.
7	Hébert SS and De Strooper B: Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci. 32:199–206. 2009.PubMed/NCBI
8	Long JM and Lahiri DK: MicroRNA-101 downregulates Alzheimer’s amyloid-β precursor protein levels in human cell cultures and is differentially expressed. Biochem Biophys Res Commun. 404:889–895. 2011.PubMed/NCBI
9	Delay C, Calon F, Mathews P and Hébert SS: Alzheimer-specific variants in the 3′UTR of Amyloid precursor protein affect microRNA function. Mol Neurodegener. 6:702011.PubMed/NCBI
10	Hébert SS, Papadopoulou AS, Smith P, et al: Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration. Hum Mol Genet. 19:3959–3969. 2010.PubMed/NCBI
11	Blennow K, Hampel H, Weiner M and Zetterberg H: Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 6:131–144. 2010. View Article : Google Scholar : PubMed/NCBI
12	Rembach A, Faux NG, Watt AD, et al: AIBL research group, Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer’s disease. Alzheimers Dement. 10:53–61. 2014.PubMed/NCBI
13	Lewczuk P, Kamrowski-Kruck H, Peters O, et al: Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer’s disease: a multicenter study. Mol Psychiatry. 15:138–145. 2010.
14	Zetterberg H, Andreasson U, Hansson O, et al: Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol. 65:1102–1107. 2008. View Article : Google Scholar : PubMed/NCBI
15	Wang WX, Huang Q, Hu Y, Stromberg AJ and Nelson PT: Patterns of microRNA expression in normal and early Alzheimer’s disease human temporal cortex: white matter versus gray matter. Acta Neuropathol. 2:193–205. 2011.PubMed/NCBI
16	Schonrock N, Ke YD, Humphreys D, et al: Neuronal microRNA deregulation in response to Alzheimer’s disease amyloid-beta. PLoS One. 5:e110702010.PubMed/NCBI
17	Hosseini HM, Fooladi AA, Nourani MR and Ghanezadeh F: The role of exosomes in infectious diseases. Inflamm Allergy Drug Targets. 1:29–37. 2013. View Article : Google Scholar : PubMed/NCBI
18	Pant S, Hilton H and Burczynski ME: The multifaceted exosome: biogenesis, role in normal and aberrant cellular function, and frontiers for pharmacological and biomarker opportunities. Biochem Pharmacol. 11:1484–1494. 2012. View Article : Google Scholar : PubMed/NCBI
19	Boon RA and Vickers KC: Intercellular transport of microRNAs. Arterioscler Thromb Vasc Biol. 33:186–192. 2013. View Article : Google Scholar : PubMed/NCBI
20	Wei PC, Tsai CH, Chiu PS and Lai SC: Matrix metalloproteinase-12 leads to elastin degradation in BALB/c mice with eosinophilic meningitis caused by Angiostrongylus cantonensis. Int J Parasitol. 41:1175–1183. 2011. View Article : Google Scholar
21	Wang WX, Rajeev BW and Stromberg AJ: The expression of microRNA miR-107 decreases early in Alzheimer’s disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci. 5:1213–1223. 2008.PubMed/NCBI
22	Liu CG, Xu KQ, Xu X, et al: 17Beta-oestradiol regulates the expression of Na⁺/K⁺-ATPase beta1-subunit, sarcoplasmic reticulum Ca²⁺-ATPase and carbonic anhydrase iv in H9C2 cells. Clin Exp Pharmacol Physiol. 34:998–1004. 2007.PubMed/NCBI
23	Dassow H and Aigner A: MicroRNAs (miRNAs) in colorectal cancer: from aberrant expression towards therapy. Curr Pharm Des. 19:1242–1252. 2013.PubMed/NCBI
24	Eulalio A, Schulte L and Vogel J: The mammalian microRNA response to bacterial infections. RNA Biol. 9:742–750. 2012. View Article : Google Scholar : PubMed/NCBI
25	Mitchell PS, Parkin RK, Kroh EM, Fritz BR and Wyman SK: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
26	Giedraitis V, Sundelöf J, Irizarry MC, et al: The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer’s disease. Neurosci Lett. 427:127–131. 2007.PubMed/NCBI
27	Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD and Remaley AT: MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 4:423–433. 2011. View Article : Google Scholar : PubMed/NCBI
28	van Leuven F: Single and multiple transgenic mice as models for Alzheimer’s disease, Prog. Neurobiol. 61:305–312. 2000.
29	Ceruti S, Colombo L, Magni G, et al: Oxygen-glucose deprivation increases the enzymatic activity and the microvesicle-mediated release of ectonucleotidases in the cells composing the blood-brain barrier. Neurochem Int. 59:259–271. 2011. View Article : Google Scholar
30	Ma R, Jiang T and Kang X: Circulating microRNAs in cancer: origin, function and application. J Exp Clin Cancer Res. 31:382012. View Article : Google Scholar : PubMed/NCBI